FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
X

Find Clinical Drug Pipeline Developments & Deals by Shanghai Fosun Pharmaceutical

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Recipient: BioNTech SE

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            The potential vaccine is one of the two most advanced candidates that BioNTech is working on with its partner Pfizer Inc and they received “fast track” status this week from the U.S. Food and Drug Administration which is designed to speed up the regulatory review process.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pretomanid

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: TB Alliance

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 16, 2020

            Details:

            The partnership with Hongqi is part of TB Alliance’s global commercialization strategy for pretomanid as part of the BPaL regimen.